Axial VC

Stately Bio is a biotechnology company that specializes in live-cell imaging technology. It utilizes patented machine learning methods to analyze cell identity, behavior, and maturation without the need for labels, allowing for real-time observation of living cells. By focusing on the balance between accurate measurement and cellular viability, Stately Bio aims to advance research and applications in cellular biology. Currently, the company operates in stealth mode, suggesting that it is in the early stages of development and may be preparing for future product launches or partnerships.

AI research assistant for biology.

Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides that possess antibody-like binding affinity. The company utilizes an innovative platform that combines molecular biology and parallel synthetic chemistry to design, synthesize, and test these cyclic peptides at an unprecedented scale. By rapidly identifying preclinical candidates with favorable pharmacological properties, Insamo aims to transform patient care by providing alternatives to injected or infused biologics, thereby facilitating easier administration through oral formulations.

Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to produce stabilized, solubilized, and catalytically optimized proteins. Utilizing advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach allows the engineering of biological molecules aimed at enhancing agricultural and pharmaceutical applications. By focusing on hyper-folded proteins, Aperiam Bio enables researchers to create more effective and durable proteins than those found in nature, ultimately contributing to advancements in various fields and improving lives.

Nalu Bio is a biotechnology company focused on producing cannabinoids, including CBD, through a proprietary chemistry-based platform rather than traditional plant extraction methods. This innovative approach allows Nalu Bio to create consistent and high-quality cannabinoid products that are free from THC, chemicals, and pesticides, while significantly reducing resource usage—utilizing 700 times less land, 70 times less water, and 14 times less energy compared to conventional methods. The company aims to set new standards in cannabinoid production for both consumer and pharmaceutical markets by ensuring purity and accessibility, thereby positioning itself to disrupt the traditional hemp extraction industry.

Meliora Therapeutics is a biotech startup focused on developing innovative cancer therapies by leveraging a machine learning-driven platform. The company aims to identify the true mechanisms of action (MOA) of oncology medications through its proprietary prediction atlas, which maps drug mechanisms. This approach streamlines the drug development process by eliminating a significant and costly phase, thereby allowing researchers to advance their work more efficiently. By focusing on the precise actions of molecules of interest, Meliora Therapeutics seeks to enhance the effectiveness of cancer treatments and contribute to life-saving medical advancements in oncology.

Network Bio is a company that specializes in creating a clinical and molecular data library aimed at advancing precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, facilitating research by allowing scientists to identify patterns and correlations. This capability is essential for the development of new treatments and diagnostic tools, contributing to more personalized healthcare solutions. Through its innovative approach, Network Bio supports the research community in addressing significant health challenges.

Think Bioscience is a company focused on advancing synthetic biology to enhance the development of medicines. It employs innovative technology to encode complex molecular objectives within microbial hosts, facilitating the identification, construction, and evolution of small molecules. By leveraging living systems, Think Bioscience aims to transform the drug discovery process, providing medical researchers with powerful tools to create better therapeutic solutions. The company's approach represents a significant evolution in the field of synthetic biology, positioning it as a leader in the quest for improved medicinal outcomes.

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biological systems through the synthesis and delivery of large DNA constructs. The company aims to harness the potential of genome engineering to create innovative solutions in medicine, enhancing the ability to manipulate genetic material for therapeutic purposes. By developing technologies that enable precise DNA writing, Replay seeks to redefine the landscape of genetic research and its applications, ultimately contributing to improved health outcomes and the treatment of various diseases.

CHARM Therapeutics is a biotechnology company focused on delivering innovative medicines by leveraging advanced 3D deep learning and drug discovery technologies. Its platform is designed to address challenging disease targets that are typically considered undruggable, thereby enhancing treatment options for patients. By utilizing cutting-edge methodologies, CHARM Therapeutics aims to develop therapeutics with transformational efficacy, ultimately assisting healthcare professionals in improving patient outcomes.

Omica is Latin America's Biomedical Data Hub. We aggregate high quality datasets for Life Science R&D. Our platform consists of an AI-enhanced EMR system linked to a multi-omics biobank.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Enable Medicine is a biotechnology company founded in 2019 by Aaron Mayer and Sunil Bodapati in Menlo Park, California. The company specializes in a bio-computational platform that facilitates the extraction of insights from diverse biological samples. Its Enable Cloud Platform offers a collaborative ecosystem equipped with tools for generating, visualizing, and analyzing various biological image formats. By providing end-to-end services that include custom panel development, data acquisition through advanced imaging technology, and spatial data analysis, Enable Medicine supports researchers, drug developers, and physicians in creating cellular maps that enhance drug discovery processes. The platform aims to reduce costs and accelerate the time required to achieve scientific insights.

Zeit Medical is a company focused on advancing the treatment of neurological injuries through innovative technology. Founded in 2019 by Urs Naber and Orestis Vardoulis, the company has developed a specialized headband that continuously monitors the electrical activity of the brain. This device integrates smoothly with existing electroencephalogram (EEG) systems and automates the pre-screening process, facilitating the annotation of extensive datasets. By identifying signature patterns in EEG readings, Zeit Medical enables physicians to diagnose and treat neurological conditions with greater precision, particularly in detecting the onset of strokes.

Options MD is a telemedicine platform focused on delivering personalized care for individuals experiencing severe and treatment-resistant mental illnesses. The company operates a treatment-matching system that utilizes artificial intelligence to pair patients with tailored treatment options. By connecting users with psychiatric experts, Options MD aims to streamline the process of finding effective depression care, ensuring that patients receive the appropriate medical attention more efficiently. Through its innovative approach, Options MD addresses the challenges faced by those seeking specialized support for their mental health conditions.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Parallel Health is a skin health company that uses genomics, the skin microbiome, and machine learning to offer end-to-end dermatology solutions. It develops a precision health platform that combines microbial genomics, big data, and AI to enable skin testing, personalized microbiome products, and custom prescriptions for consumers, patients, and clinicians, integrating derm telehealth, microbiome diagnostics, and data-driven skincare therapies to address diverse skin conditions with tailored treatments.